Lanean...
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15–25% of all metastatic melanoma patients. It currently does no...
Gorde:
| Argitaratua izan da: | Ther Adv Med Oncol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5502949/ https://ncbi.nlm.nih.gov/pubmed/28717400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834017708160 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|